person · Reporting owner

MUELLER PETER

Disclosed activity across 2 companies

Tapewire entity: 16509
SEC CIK: 0001256126

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BioXcel Therapeutics, Inc.BTAI · Entity 8380	Director	January 09, 2026	January 12, 2026
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875	EVP, Global R&D, CSO	June 16, 2014	June 18, 2014

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BioXcel Therapeutics, Inc.

Report date January 09, 2026 · Filed January 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09	Direct	17,000	Reported balance After 2026-01-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.

VERTEX PHARMACEUTICALS INC / MA

Report date June 16, 2014 · Filed June 18, 2014

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	151,017	Reported balance After 2014-06-16 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2014-06-16 · Exercise / conversion · Acquired 7,500 · Balance 151,017
Common StockSEC Table I · non-derivative	Direct	146,614	Reported balance After 2014-06-16 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2014-06-16 · Sale · Disposed 4,403 · Balance 146,614 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96). F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Common StockSEC Table I · non-derivative	Direct	145,114	Reported balance After 2014-06-16 transaction · row 3 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 3 · 2014-06-16 · Sale · Disposed 1,500 · Balance 145,114 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86).
Common StockSEC Table I · non-derivative	Direct	143,517	Reported balance After 2014-06-16 transaction · row 5 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 5 · 2014-06-16 · Sale · Disposed 1,000 · Balance 143,517 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99).
Common StockSEC Table I · non-derivative	Direct	144,517	Reported balance After 2014-06-16 transaction · row 4 1 source row Row 4 · 2014-06-16 · Sale · Disposed 597 · Balance 144,517 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95).
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.16 · Expires 2018-07-23	Direct	15,500	Reported balance After 2014-06-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2014-06-16 · Exercise / conversion · Disposed 7,500 · Balance 15,500 F8: Fully vested.
Common StockSEC Table I · non-derivative	Indirect401(k)	4,770	Reported balance Holding disclosure · report date 2014-06-16 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 4,770
Common StockSEC Table I · non-derivative	IndirectRevocable Trust	5,568	Reported balance Holding disclosure · report date 2014-06-16 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 5,568
Common StockSEC Table I · non-derivative	IndirectCommon stock held in trust	15,233	Reported balance Holding disclosure · report date 2014-06-16 · row 8 Holding and transaction disclosures are not merged. 1 source row Row 8 · Balance 15,233 F7: Common stock held in grantor retained annuity trust.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96).

F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86).

F5: Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95).

F6: Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99).

F7: Common stock held in grantor retained annuity trust.

F8: Fully vested.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 15, 2011 Filed Jun 16, 2011 18:47 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Options · Derivative	2,500	$0.00 Strike: $10.41	$0.00	Disclosure SEC source: 0001209191-11-034941 · doc4.xml · derivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 2,500 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document
June 15, 2011 Filed Jun 16, 2011 18:47 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	700	$47.14	$32,998.00	Disclosure SEC source: 0001209191-11-034941 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,735 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $47.14 (range $47.00 to $47.41). Read SEC document
June 15, 2011 Filed Jun 16, 2011 18:47 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,800	$46.50	$83,700.00	Disclosure SEC source: 0001209191-11-034941 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,435 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $46.50 (range $46.08 to $46.96). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
June 15, 2011 Filed Jun 16, 2011 18:47 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	2,500	$10.41	$26,025.00	Disclosure SEC source: 0001209191-11-034941 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 16, 2011 Filed May 18, 2011 17:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Options · Derivative	2,500	$0.00 Strike: $10.41	$0.00	Disclosure SEC source: 0001209191-11-029274 · doc4.xml · derivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,300 Underlying: Common Stock · 2,500 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document
May 16, 2011 Filed May 18, 2011 17:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,700	$57.21	$97,257.00	Disclosure SEC source: 0001209191-11-029274 · doc4.xml · nonDerivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,735 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $57.21 (range $57.00 to $57.49). Read SEC document
May 16, 2011 Filed May 18, 2011 17:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	700	$56.79	$39,753.00	Disclosure SEC source: 0001209191-11-029274 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,435 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $56.79 (range $56.61 to $56.92). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
May 16, 2011 Filed May 18, 2011 17:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	100	$55.44	$5,544.00	Disclosure SEC source: 0001209191-11-029274 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,135 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. Read SEC document
May 16, 2011 Filed May 18, 2011 17:45 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	2,500	$10.41	$26,025.00	Disclosure SEC source: 0001209191-11-029274 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 25, 2011 Filed Apr 26, 2011 19:41 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	12,500	$0.00 Strike: $16.32	$0.00	Disclosure SEC source: 0001209191-11-024396 · doc4.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 12,500 shares Expires 2013-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document
April 25, 2011 Filed Apr 26, 2011 19:41 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	12,500	$50.00	$625,000.00	Disclosure SEC source: 0001209191-11-024396 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,735 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. Read SEC document
April 25, 2011 Filed Apr 26, 2011 19:41 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	12,500	$16.32	$204,000.00	Disclosure SEC source: 0001209191-11-024396 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 15, 2011 Filed Apr 19, 2011 20:29 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	2,500	$0.00 Strike: $10.41	$0.00	Disclosure SEC source: 0001209191-11-023372 · doc4.xml · derivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: Common Stock · 2,500 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document
April 15, 2011 Filed Apr 19, 2011 20:29 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,200	$47.71	$57,252.00	Disclosure SEC source: 0001209191-11-023372 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,735 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $47.71 (range $47.60 to $48.10). Read SEC document
April 15, 2011 Filed Apr 19, 2011 20:29 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,300	$47.28	$61,464.00	Disclosure SEC source: 0001209191-11-023372 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,935 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $47.28 (range $46.88 to $47.58). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
April 15, 2011 Filed Apr 19, 2011 20:29 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	2,500	$10.41	$26,025.00	Disclosure SEC source: 0001209191-11-023372 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 11, 2011 Filed Apr 13, 2011 18:01 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	2,500	$0.00 Strike: $10.41	$0.00	Disclosure SEC source: 0001209191-11-022756 · doc4.xml · derivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,300 Underlying: Common Stock · 2,500 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document
April 11, 2011 Filed Apr 13, 2011 18:01 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	37,500	$0.00 Strike: $16.32	$0.00	Disclosure SEC source: 0001209191-11-022756 · doc4.xml · derivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 37,500 shares Expires 2013-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document
April 11, 2011 Filed Apr 13, 2011 18:01 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	21,135	$48.20	$1,018,707.00	Disclosure SEC source: 0001209191-11-022756 · doc4.xml · nonDerivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,735 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a wieghted average price of $48.20 (range $48.00 to $48.84). Read SEC document
April 11, 2011 Filed Apr 13, 2011 18:01 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	18,865	$47.83	$902,312.95	Disclosure SEC source: 0001209191-11-022756 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,870 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $47.83 (range $47.57 to $47.99). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
April 11, 2011 Filed Apr 13, 2011 18:01 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	37,500	$16.32	$612,000.00	Disclosure SEC source: 0001209191-11-022756 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 11, 2011 Filed Apr 13, 2011 18:01 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	2,500	$10.41	$26,025.00	Disclosure SEC source: 0001209191-11-022756 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 03, 2011 Filed Feb 7, 2011 19:56 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantStock Option · Derivative	72,500	$0.00 Strike: $38.80	$0.00	Disclosure SEC source: 0000875320-11-000011 · edgar.xml · derivative · entry 3 MUELLER PETER · CIK 0001256126 · Director · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document
February 03, 2011 Filed Feb 7, 2011 19:56 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	14,501	$0.01	$145.01	Disclosure SEC source: 0000875320-11-000011 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · Director · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,735 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document
November 15, 2010 Filed Nov 16, 2010 21:20 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	1,600	$0.00 Strike: $10.41	$0.00	Disclosure SEC source: 0000875320-10-000058 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,800 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document
November 15, 2010 Filed Nov 16, 2010 21:20 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,600	$34.43	$55,088.00	Disclosure SEC source: 0000875320-10-000058 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,234 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $34.43 (range $33.95 to $34.57). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
November 15, 2010 Filed Nov 16, 2010 21:20 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	1,600	$10.41	$16,656.00	Disclosure SEC source: 0000875320-10-000058 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 15, 2010 Filed Oct 18, 2010 19:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	1,600	$0.00 Strike: $10.41	$0.00	Disclosure SEC source: 0000875320-10-000053 · edgar.xml · derivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,400 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document
October 15, 2010 Filed Oct 18, 2010 19:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	330	$36.02	$11,886.60	Disclosure SEC source: 0000875320-10-000053 · edgar.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,234 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $36.02 (range ($35.96 to $36.10). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
October 15, 2010 Filed Oct 18, 2010 19:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,270	$35.55	$45,148.50	Disclosure SEC source: 0000875320-10-000053 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,564 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $35.55 (range $34.88 to $35.87). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
October 15, 2010 Filed Oct 18, 2010 19:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	1,600	$10.41	$16,656.00	Disclosure SEC source: 0000875320-10-000053 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 15, 2010 Filed Sep 16, 2010 19:53 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	1,600	$0.00 Strike: $10.41	$0.00	Disclosure SEC source: 0000875320-10-000050 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document
September 15, 2010 Filed Sep 16, 2010 19:53 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,600	$37.22	$59,552.00	Disclosure SEC source: 0000875320-10-000050 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,234 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $37.22 (range $37.08 to $37.36). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
September 15, 2010 Filed Sep 16, 2010 19:53 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	1,600	$10.41	$16,656.00	Disclosure SEC source: 0000875320-10-000050 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 16, 2010 Filed Aug 17, 2010 18:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	1,600	$0.00 Strike: $10.41	$0.00	Disclosure SEC source: 0000875320-10-000049 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,600 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document
August 16, 2010 Filed Aug 17, 2010 18:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,600	$36.38	$58,208.00	Disclosure SEC source: 0000875320-10-000049 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,234 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $36.38 (range $36.02 to $36.54). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
August 16, 2010 Filed Aug 17, 2010 18:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	1,600	$10.41	$16,656.00	Disclosure SEC source: 0000875320-10-000049 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 15, 2010 Filed Jul 16, 2010 20:02 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	1,600	$0.00 Strike: $10.41	$0.00	Disclosure SEC source: 0000875320-10-000047 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document
July 15, 2010 Filed Jul 16, 2010 20:02 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,600	$34.24	$54,784.00	Disclosure SEC source: 0000875320-10-000047 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,234 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $34.24 (range $34.04 to $34.50). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
July 15, 2010 Filed Jul 16, 2010 20:02 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	1,600	$10.41	$16,656.00	Disclosure SEC source: 0000875320-10-000047 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 14, 2010 Filed Jul 16, 2010 20:02 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantStock Option · Derivative	36,250	$0.00 Strike: $33.82	$0.00	Disclosure SEC source: 0000875320-10-000047 · edgar.xml · derivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,250 Underlying: Common Stock · 36,250 shares Expires 2020-07-13 F5 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/14/2010. Read SEC document
June 15, 2010 Filed Jun 16, 2010 16:28 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	1,600	$0.00 Strike: $10.41	$0.00	Disclosure SEC source: 0000875320-10-000034 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,800 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document
June 15, 2010 Filed Jun 16, 2010 16:28 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,600	$34.93	$55,888.00	Disclosure SEC source: 0000875320-10-000034 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,234 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $34.93 (range $34.78 to $35.09). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
June 15, 2010 Filed Jun 16, 2010 16:28 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	1,600	$10.41	$16,656.00	Disclosure SEC source: 0000875320-10-000034 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 17, 2010 Filed May 18, 2010 19:16 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	1,600	$0.00 Strike: $10.41	$0.00	Disclosure SEC source: 0000875320-10-000023 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document
May 17, 2010 Filed May 18, 2010 19:16 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,600	$37.39	$59,824.00	Disclosure SEC source: 0000875320-10-000023 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,234 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $37.39 (range $36.87 to $37.87). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
May 17, 2010 Filed May 18, 2010 19:16 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	1,600	$10.41	$16,656.00	Disclosure SEC source: 0000875320-10-000023 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 07, 2010 Filed May 10, 2010 20:53 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	2,987	$36.18	$108,069.66	Disclosure SEC source: 0000875320-10-000022 · edgar.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,234 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $36.18 (range $36.02 to $36.44). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
May 07, 2010 Filed May 10, 2010 20:53 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	3,284	$35.78	$117,501.52	Disclosure SEC source: 0000875320-10-000022 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,221 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $35.78 (range $35.11 to $36.00). F4 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
April 15, 2010 Filed Apr 16, 2010 19:50 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	1,600	$0.00 Strike: $10.41	$0.00	Disclosure SEC source: 0000875320-10-000018 · edgar.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 1,600 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.